FDA Accepts Supplemental New Drug Application for Encorafenib, Binimetinib Combination in NSCLC
April 6th 2023The application is based on the PHAROS trial, which met its primary endpoint of objective response rate in patients with metastatic non–small cell lung cancer with a BRAF V600E mutation.
Read More